(Answered) NR-565 Week 1 Pharmacogenomics Discussion

COURSE  

NR-565: Advanced Pharmacology Fundamentals

In your initial post, respond to the following scenario (Hint: use the pharmgkb website to guide your responses):

  1. Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive patient the nurse practitioner orders HLA-B*5701 allele genetic testing. The test confirms that the patient carries the HLA-B*5701 allele.
  • Describe what these results mean.
  • Should the nurse practitioner prescribe abacavir in this case? If not, state why.
  1. A patient is prescribed antiplatelet therapy (clopidogrel) following an acute myocardial infarction (MI). Six months later, the patient suffers another acute MI. The patient has been adherent to therapy and the nurse practitioner suspects that clopidrogel may have been ineffective. How might genetic testing have been beneficial in this case?
  2. Identify 2 limitations of pharmacogenomics testing. Explain.
  3. Identify 2 ethical concerns of using pharmacogenomics testing. Explain.

ANSWER   

Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive patient the nurse practitioner orders HLA-B*5701 allele genetic testing. The test confirms that the patient carries the HLA-B*5701 allele.

The HLA-B*5701 is genetic testing used to determine the potential risk for severe side effects from the antiviral medication abacavir (De Spiegelaere et al., 2015). The HLA-B gene has an impact on how the immune system responds and recognizes various pathogens while mediating hypersensitivity reactions (De Spiegelaere et al., 2015). If a copy of the HLA-B*5701 is positive, it determines there is at least one copy of the allele. This test is run by obtaining a sample of the patient’s saliva or blood. Abacavir is a nucleoside reverse transcriptase inhibitor used as an antiretroviral therapy in HIV…..please click the icon below to purchase the answer at $5